SearchSkip to Search Results
- 3Azarmi, Shirzad
- 3Löbenberg, Raimar
- 3Roa, Wilson H.
- 2Al-Hallak, MHD Kamal
- 1Al-Hallak, K.
- 1Al-Hallak, M. H. D. Kamal
This is an abstract of a presentation made at the conference titled \"The Aerosol Society Drug Delivery to the Lungs 20,\" at the Edinburgh International Conference Centre, Scotland, UK, December 9-11, 2009.
Inhalable nanoparticles in lung cancer treatment; efficacy, safety, distribution and nanoparticle-macrophage interactionsDownload
In 2002, lung cancer was responsible for 17.6% of the total worldwide deaths from cancer. Beyond the three traditional forms of cancer treatment, surgery, radiation therapy, and chemotherapy, targeted drug delivery therapy has shown to be a potential treatment option. The design of a successful...
Macrophages are the primary cells of innate immunity that provide the first line of defence against any external stimuli. Their phagocytic properties enable them to engulf invading microbes or foreign particles. The phagocytic capability of macrophages plays a major role in interfering with drug...
The changing causal foundations of cancer-related symptom clustering during the final month of palliative care: A longitudinal studyDownload
Background: Symptoms tend to occur in what have been called symptom clusters. Early symptom cluster research was imprecise regarding the causal foundations of the coordinations between specific symptoms, and was silent on whether the relationships between symptoms remained stable over time. This...
Lung cancer has the highest mortality rates of all cancers worldwide, with a 5-year survival rate less than 15%. Screening methods are in need for the high risk population, as lung cancer is asymptomatic in its early stages. Proper screening methods would allow earlier diagnosis and curative...